Effects of acrolein on human platelet aggregation.
Acrolein, a component of tobacco smoke, potentiated platelet aggregation and increased thromboxane A2 (TXA2) formation caused by thrombin and arachidonic acid (AA). Acrolein produced these effects at concentrations in the range 50-5000 microM. Acrolein had no effect on platelet responses to ADP, epinephrine, collagen or the ionophore A23187. Acrolein increased the mobilization of [3H]arachidonic acid from prelabelled platelets in response to thrombin and arachidonic acid. The increased availability of substrate could partly explain the enhanced production of TXA2 and increased aggregation observed in the presence of acrolein. These findings could provide an explanation for the increased incidence of vascular disease in cigarette smokers.
Selley
M L
ML
Australian National University, John Curtin School of Medical Research, Division of Clinical Sciences, Woden Valley Hospital, Garran, ACT.
Bartlett
M R
MR
McGuiness
J A
JA
Ardlie
N G
NG
D000171:Acrolein / Q000494:pharmacology*; D000447:Aldehydes / Q000494:pharmacology*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D012907:Smoking / Q000097:blood / Q000503:physiopathology*; D013917:Thrombin / Q000494:pharmacology; D013928:Thromboxane A2 / Q000096:biosynthesis; D013929:Thromboxane B2 / Q000097:blood
D000447:Aldehydes; D001095:Arachidonic Acids; D016718:Arachidonic Acid; D013929:Thromboxane B2; D013928:Thromboxane A2; D000171:Acrolein; D013917:Thrombin